Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CM529D
- Development stage
- Unknown
- Lead developer
- Keymed Biosciences
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CM529D (also known as CM529D1) is a bispecific antibody-drug conjugate (ADC) targeting both delta-like protein 3 (DLL3) and seizure protein 6 homolog (SEZ6). Developed by Keymed Biosciences using its proprietary KeyMedSTAR™ ADC platform, CM529D is designed to treat advanced solid tumors, particularly small cell lung cancer (SCLC) and other neuroendocrine neoplasms. The drug consists of a bispecific antibody targeting DLL3 and SEZ6, conjugated to a topoisomerase I inhibitor payload (a camptothecin derivative) via a cleavable linker. By simultaneously targeting DLL3 and SEZ6, CM529D aims to overcome tumor heterogeneity and antigen downregulation, which are common resistance mechanisms in SCLC. It is currently in Phase I/II clinical development.
02
Targets
DLL3 (Delta-like ligand 3)SEZ6
Beyond the preview
Go deeper on CM529D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CM529D.